Andrew A Hicks completed a Ph.D. in Molecular Neurobiology in 1989 within the Molecular Neurobiology Unit of the MRC based at the site of the Laboratory of Molecular Biology in Cambridge. This foundation was consolidated during 2-year position as Senior Research Associate for Neurosciences at Peterhouse, Cambridge, examining a role for neurotransmitter receptors in psychiatric and neurological disease, followed by an almost seven-year period as Project Leader in the CNRS laboratory of Jacques Mallet in Paris, investigating the molecular mechanisms of synaptic plasticity in the brain. In 1998 he took a position as Project Leader at deCODE Genetics Inc. in Iceland, where he stayed until 2007 directing the movement disorder projects (working mainly with Parkinson’s disease and Restless Legs Syndrome) alongside his research into other neurological disorders (such as addiction and Alzheimer’s disease). Since 2007 he has worked at the Institute for Biomedicine, where he is both Vice Head of the Institute and leads the newly formed Translational Genomics group. He helps set and execute science strategy and coordinates the use of Institute resources in many of the outreach research activities. His current research activities include projects on Parkinson's disease, epilepsy, sleep disorders, and pain chronicity, alongside the genetics of complex traits.
Andrew A Hicks completed a Ph.D. in Molecular Neurobiology in 1989 within the Molecular Neurobiology Unit of the MRC based at the site of the Laboratory of Molecular Biology in Cambridge. This foundation was consolidated during 2-year position as Senior Research Associate for Neurosciences at Peterhouse, Cambridge, examining a role for neurotransmitter receptors in psychiatric and neurological disease, followed by an almost seven-year period as Project Leader in the CNRS laboratory of Jacques Mallet in Paris, investigating the molecular mechanisms of synaptic plasticity in the brain. In 1998 he took a position as Project Leader at deCODE Genetics Inc. in Iceland, where he stayed until 2007 directing the movement disorder projects (working mainly with Parkinson’s disease and Restless Legs Syndrome) alongside his research into other neurological disorders (such as addiction and Alzheimer’s disease). Since 2007 he has worked at the Institute for Biomedicine, where he is both Vice Head of the Institute and leads the newly formed Translational Genomics group. He helps set and execute science strategy and coordinates the use of Institute resources in many of the outreach research activities. His current research activities include projects on Parkinson's disease, epilepsy, sleep disorders, and pain chronicity, alongside the genetics of complex traits.